 AUSTIN, Texas, Aug. 23, 2022 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the Phase 12a ReSPECT-GBMTM dose escalation clinical trial evaluating the Companys lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome 186RNL, in recurrent glioblastoma in an oral presentation at the European Society for Medical Oncology ESMO Congress 2022, being held September 9-13, 2022 in Paris, France. 